Clinical Trial: mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line

U.S., July 15 -- ClinicalTrials.gov registry received information related to the study (NCT07062536) titled 'mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line' on Feb. 20.

Brief Summary: In second line with advanced or recurrent biliary tract cancer refractory to first line gemcitabine plus cisplatin,efficacy of mFOLFOX/FOLFIRI vs mFOLFOX will be evaluated at randomized phase 2 trial.

Study Start Date: Aug. 01

Study Type: INTERVENTIONAL

Condition: Biliary Cancer Metastatic

Intervention: DRUG: Oxaliplatin, 5FU, leucovorin

Administered as a single regimen every 2weeks

DRUG: Oxaliplatin, 5FU, leucovorin/Irinotecan , 5FU, leucovorin,

Administered alternately every 2weeks

Recruitment Status: NOT_YE...